A Chinese drug research and development outsourcing platform + an American gene analysis

The drug Wuxi recently bought a 65 million dollar cash for the American company NextCODE, which specializes in genetic and bioinformatics analysis, and merged NextCODE with its own gene center into a new company, the drug Wuxi NextCODE gene (Wuxi NextCODE Genomics). The business will start in Shanghai and radiate to Cambridge, Massachusetts, Reykjavik and Iceland.

NextCODE is base in the United States and Iceland, a genetic analysis and bioinformatics company, split from Decode, in October 2013 to obtain decode developed gene clinical diagnostic technology for the five year exclusive authorization.

NextCODE has a genetic sequencing analysis platform and database that can help clinicians and researchers diagnose and treat diseases using a new generation of genetic sequencing data. NextCODE combines the world's only population-wide genome analysis system with the world's largest clinical gene-controlled database, enabling clinicians and researchers worldwide to store, view and analyze their genetic data in real time, based on a single base resolution, in any Web browser, and can work with other clinicians and researchers to cooperate to more effectively solve the related medical problems.

The drug Wuxi was established in 2011, and is an outsourcing CRO platform for Drug research and development by providing a genetic sequencing solution to personalized medical care. The genome Center provides a complete solution for all types of drug development projects from discovery, preclinical, clinical development, to personalized care.

The company also launched an app called Handheld chemistry, global research and development personnel in mobile phones and other mobile clients more convenient to order a variety of organic small molecular compounds, and online inquiry, quotation, order confirmation, project progress inquiries, delivery confirmation, payment and other functions, to achieve on-line and offline real-time communication.

An information service and a drug-selling together, personalized medical and C2B research and development of the future.